CA
NZ
UK
AU
IND
US
…
Biotron Limited, a biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia. The company's lead antiviral drug is BIT225 for the treatment of SARS-CoV-2, HIV-1, hepatitis C virus, hepatitis B virus (HBV), influenza, and dengue virus infections. The company was incorporated in 1999 and is based in Sydney, Australia.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Biotron Limited is an Australian biotechnology company developing antiviral therapeutics targeting viral infections through preclinical and clinical-stage programmes. Long-term growth may be driven by clinical trial progress and regulatory milestones, potential licensing or partnership transactions, and sustained demand for effective antiviral treatments, which could support value creation if programmes advance.
Key investment risks include high clinical and regulatory failure risk, significant financing and dilution risk typical of small-cap clinical-stage biotechs, and limited liquidity and transparency associated with its PINK listing.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
| Income before tax | -0.32M | -3.44M | -4.92M | -2.78M | -3.19M |
| Net income | -0.32M | -3.44M | -3.49M | -2.78M | -3.19M |
| Selling general administrative | 0.77M | 0.53M | 1.63M | 1.12M | 1.13M |
| Selling and marketing expenses | 0.74M | 0.87M | - | - | - |
| Gross profit | 1.81M | 1.60M | 1.39M | 1.51M | 1.41M |
| Reconciled depreciation | - | - | 0.04M | 0.05M | 0.05M |
| Ebit | -0.34M | -3.51M | -3.49M | -2.78M | -3.19M |
| Ebitda | -0.33M | -3.50M | -3.45M | -2.73M | -3.15M |
| Depreciation and amortization | 0.00M | 0.00M | 0.04M | 0.05M | 0.05M |
| Operating income | -0.34M | -3.51M | -5.04M | -2.78M | -3.19M |
| Other operating expenses | 2.15M | 5.15M | 5.04M | 4.34M | 4.67M |
| Interest expense | - | 0.00M | 0.00M | 0.01M | 0.00M |
| Tax provision | - | - | 0.00M | 0.00M | 0.00M |
| Interest income | - | - | 0.12M | 0.00M | 0.01M |
| Net interest income | - | - | 0.12M | -0.00M | 0.01M |
| Income tax expense | - | -1.65M | -1.43M | 1.56M | 1.46M |
| Total revenue | 1.81M | 1.65M | 1.43M | 1.56M | 1.46M |
| Total operating expenses | 2.15M | 5.15M | 5.00M | 4.34M | 4.67M |
| Cost of revenue | - | 0.04M | 0.04M | 0.05M | 0.05M |
| Total other income expense net | 0.02M | 0.07M | 0.12M | -0.00M | 0.01M |
| Net income from continuing ops | - | - | -3.49M | -2.78M | -3.19M |
| Net income applicable to common shares | - | - | -3.49M | -2.78M | -3.19M |
| Breakdown | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
| Total assets | 0.98M | 0.49M | 4.14M | 1.91M | 4.33M |
| Other current assets | 0.02M | 0.03M | 0.02M | 0.02M | 0.05M |
| Total liab | 0.43M | 0.74M | 0.96M | 0.81M | 0.46M |
| Total stockholder equity | 0.55M | -0.24M | 3.17M | 1.09M | 3.86M |
| Other current liab | 0.34M | 0.44M | - | 0.33M | 0.31M |
| Common stock | 59.32M | 56.91M | 56.89M | 52.84M | 52.84M |
| Capital stock | - | - | 56.89M | 52.84M | 52.84M |
| Retained earnings | -58.77M | -58.68M | -55.26M | -51.84M | -49.09M |
| Other liab | - | - | - | 0.02M | 0.01M |
| Other assets | - | - | 0.05M | 0.05M | 0.03M |
| Cash | 0.93M | 0.39M | 3.98M | 1.74M | 4.21M |
| Total current liabilities | 0.43M | 0.74M | 0.96M | 0.75M | 0.45M |
| Net debt | -0.93M | -0.39M | - | -1.66M | -4.20M |
| Short term debt | - | 0.01M | - | 0.03M | 0.01M |
| Short long term debt total | - | 0.01M | - | 0.08M | 0.01M |
| Other stockholder equity | - | 1.52M | 0.02M | 0.09M | 0.11M |
| Property plant equipment | - | - | 0.05M | 0.09M | 0.03M |
| Total current assets | 0.96M | 0.43M | 4.03M | 1.76M | 4.26M |
| Net tangible assets | - | - | 3.17M | 1.09M | 3.86M |
| Net receivables | - | 0.02M | 0.02M | - | - |
| Inventory | - | -0.00M | - | - | - |
| Accounts payable | 0.09M | 0.29M | 0.29M | 0.39M | 0.14M |
| Accumulated other comprehensive income | - | 0.00M | - | 0.09M | 0.11M |
| Non currrent assets other | 0.02M | 0.05M | 0.05M | 0.05M | 0.03M |
| Non current assets total | 0.03M | 0.07M | 0.10M | 0.14M | 0.06M |
| Capital lease obligations | - | - | 0.05M | 0.08M | 0.01M |
| Breakdown | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
| Investments | - | - | - | - | -0.01M |
| Change to liabilities | - | - | 0.15M | 0.20M | -0.37M |
| Total cashflows from investing activities | -0.00M | - | - | - | -0.01M |
| Net borrowings | - | - | -0.04M | -0.03M | -0.04M |
| Total cash from financing activities | 1.11M | -0.02M | 5.53M | -0.03M | -0.04M |
| Change to operating activities | - | - | -0.03M | 0.01M | 0.01M |
| Net income | -0.32M | -3.44M | -3.49M | -2.78M | -3.19M |
| Change in cash | 0.54M | -3.59M | 2.24M | -2.47M | -3.45M |
| Begin period cash flow | 0.39M | 3.98M | 1.74M | 4.21M | 7.66M |
| End period cash flow | 0.93M | 0.39M | 3.98M | 1.74M | 4.21M |
| Total cash from operating activities | -0.57M | -3.57M | -3.29M | -2.44M | -3.41M |
| Issuance of capital stock | - | - | 6.00M | - | - |
| Depreciation | 0.01M | 0.04M | 0.04M | 0.05M | 0.05M |
| Sale purchase of stock | - | - | -0.43M | - | - |
| Other cashflows from financing activities | 1.11M | 0.02M | -0.04M | -0.03M | -0.04M |
| Change to netincome | - | - | 0.04M | 0.09M | 0.10M |
| Capital expenditures | 0.00M | 0.00M | 0.00M | 0.00M | 0.01M |
| Change in working capital | 0.01M | 0.04M | 0.12M | 0.21M | -0.36M |
| Stock based compensation | - | - | - | 0.01M | 0.08M |
| Other non cash items | -0.27M | -0.13M | 0.04M | 0.09M | 0.10M |
| Free cash flow | -0.57M | -3.57M | -3.29M | -2.44M | -3.41M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| BITRF Biotron Limited |
- -% |
0.00 | - | - | 1010.23 | 44.87 | 238.66 | 11.27 |
| NVO Novo Nordisk A/S |
0.86 2.20% |
40.00 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
18.88 3.50% |
558.88 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
109.12 13.33% |
927.89 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Biotron Limited, a biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia. The company's lead antiviral drug is BIT225 for the treatment of SARS-CoV-2, HIV-1, hepatitis C virus, hepatitis B virus (HBV), influenza, and dengue virus infections. The company was incorporated in 1999 and is based in Sydney, Australia.
| Name | Title | Year Born |
|---|---|---|
| Dr. Michelle Miller BSc., GCertAppFin, MSc., Ph.D. | MD & Exec. Director | NA |
| Mr. Peter James Nightingale B.Econ, CA | Company Sec. | 1957 |
| Dr. Stephen L. Becker M.D. | Chief Medical Officer | NA |
| Dr. Michelle Miller BSc., GCertAppFin, MSc., Ph.D. | MD & Executive Director | NA |
| Mr. Peter James Nightingale B.Econ, CA | Company Secretary | 1957 |
| Mr. Marcelo Mora ACIS, B.Bus Aasa | Company Secretary | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.82%
Communication Services
-0.22%
Consumer Cyclical
-0.13%
Consumer Defensive
+0.32%
Energy
+0.15%
Financial Services
-0.85%
Financials
+2.34%
Healthcare
-1.28%
Industrials
-0.96%
Real Estate
-0.38%
Technology
-2.73%
Utilities
-0.31%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...